Table 1.
Baseline patient and tumor characteristics
| Overall (n = 21) | |
|---|---|
| Age, median (range) | 62 (46–76) |
| Sex | |
| Male | 19 (90%) |
| Female | 2 (10%) |
| ECOG performance status | |
| 0 | 15 (71%) |
| 1 | 6 (29%) |
| Primary tumor location | |
| Gastric | 5 (24%) |
| GEJ Siewert type 1 | 1 (5%) |
| GEJ Siewert type 2 | 9 (43%) |
| GEJ Siewert type 3 | 6 (29%) |
| Clinical T stage | |
| T2 | 4 (19%) |
| T3 | 15 (71%) |
| T4a | 2 (10%) |
| Clinical N stage | |
| N0 | 5 (24%) |
| N1 | 11 (52%) |
| N2 | 4 (19%) |
| N3 | 1 (5%) |
| AJCC clinical stage68 | |
| IB | 2 (10%) |
| IIA | 4 (19%) |
| IIB | 9 (43%) |
| IIIA | 5 (24%) |
| IIIB | 1 (5%) |
| Lauren classification | |
| Intestinal | 16 (76%) |
| Diffuse/mixed | 4 (19%) |
| Indeterminate | 1 (5%) |
| MMR status | |
| MMR proficient | 18 (86%) |
| MMR deficienta | 3 (14%) |
| PD-L1 CPSb | |
| CPS ≥ 1 | 18 (90%) |
| CPS ≥ 5 | 14 (70%) |
| CPS ≥ 10 | 4 (20%) |
AJCC, American Joint Committee on Cancer.
aOne patient with a dMMR tumor did not undergo surgery and was excluded from efficacy and translational endpoints.
bPD-L1 CPS was available for 20 patients.